ReviewAntibiotics (Basel, Switzerland)2015
Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection.
Review in Antibiotics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03200093 (Secondary Prophylaxis With Oral Vancomycin for Clostridium Difficile Recurrence), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Secondary Prophylaxis With Oral Vancomycin for Clostridium Difficile Recurrence: A Randomized Control Study
Who cites it
33 citing papers in PubMed.
- Trial
- Long-Term Antibiotic-Driven Gut Microbiota Disruption Promotes ToxigenicInfection and drug resistance · 2026Article
- Management of Clostridioides difficile infection: an Italian Delphi consensus.The Journal of antimicrobial chemotherapy · 2024Article
- Review
- Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases.Journal of personalized medicine · 2024Review
- Multi-omics analysis of hospital-acquired diarrhoeal patients reveals biomarkers of enterococcal proliferation and Clostridioides difficile infection.Nature communications · 2023Article
- A computational method to dissect colonization resistance of the gut microbiota against pathogens.Cell reports methods · 2023Article
- Membrane Vesicles of ToxigenicAntioxidants (Basel, Switzerland) · 2023Article
- The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy forAntibiotics (Basel, Switzerland) · 2023Review
- Review
- Gut metabolites predict Clostridioides difficile recurrence.Microbiome · 2022Article
- Article
- Children gut microbiota exhibits a different composition and metabolic profile afterFrontiers in microbiology · 2022Article
- The varying effects of antibiotics on gut microbiota.AMB Express · 2021Review
- The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases.International journal of molecular sciences · 2021Review
- Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection.PLoS computational biology · 2021Article
- A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia.Diagnostic microbiology and infectious disease · 2020Article
- Microbiota inBiomedicines · 2020Article
- Insights into the Role of Human Gut Microbiota inMicroorganisms · 2020Review
- Comorbid status and the faecal microbial transplantation failure in treatment of recurrent Clostridioides difficile infection - pilot prospective observational cohort study.BMC infectious diseases · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile infection (CDI) is the most important cause of nosocomial diarrhea. Broad-spectrum antimicrobials have profound detrimental effects on the structure and diversity of the indigenous intestinal microbiota. These alterations often impair colonization resistance, allowing the establishment and proliferation of C. difficile in the gut. Studies involving animal models have begun to decipher the precise mechanisms by which the intestinal microbiota mediates colonization resistance against C. difficile and numerous investigations have described gut microbiota alterations associated with C. difficile colonization or infection in human subjects. Fecal microbiota transplantation (FMT) is a highly effective approach for the treatment of recurrent CDI that allows the restoration of a healthy intestinal ecosystem via infusion of fecal material from a healthy donor. The recovery of the intestinal microbiota after FMT has been examined in a few reports and work is being done to develop custom bacterial community preparations that could be used as a replacement for fecal material.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.